Huber Martin H. Jr.
SEC-identified person · CIK 1653276 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Actuate Therapeutics, INC. ACTU | Director | filed 2026 - 2026 |
| Syndax Pharmaceuticals Inc SNDX | Director | filed 2021 - 2026 |
| Mersana Therapeutics, Inc. [MRSN] | Director · President, CEO | filed 2020 - 2026 |
| Xilio Therapeutics, Inc. XLO | President of R&D and CMO | filed 2021 - 2023 |
| Tesaro, Inc. TSRO | Sr. VP, Chief Medical Officer | filed 2015 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.